Arrayit Corporation Offers Million Dollar Biomarker Discovery Service

SUNNYVALE, CA--(Marketwire - September 10, 2009) - Arrayit Corporation (OTCBB: ARYC), a proprietary life sciences technology leader, is making available a Biomarker Discovery Service capable of identifying multiple new major genetic links for human disease states which have remained a mystery for years. In separate technology collaborations, Arrayit has conducted confidential experiments which have successfully proven the unique capabilities of the custom Arrayit products and protocols employed in the Biomarker Discovery Service. Publications are expected from the respective technology collaborators.

Paul K. Haje, VP of Sales and Marketing, stated, “By identifying the genes, scientists can develop therapies and drugs that take advantage of Arrayit’s unique insight to substantially correct or cure the disease states.”

Arrayit offers a Biomarker Discovery Program wherein DNA or RNA samples are analyzed on a custom microarray -- a small glass substrate containing a proprietary representation of the entire human genome -- for a contract fee that ranges between 100K and one million dollars per experiment. Arrayit retains a small percentage of each discovery as a downstream royalty, with the specific discoveries remaining the confidential property of the client.

About Arrayit Corporation

Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 650 products to a customer base of more than 2,500 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit www.arrayit.com for more information.

Safe Harbor Statement

Except for historical information contained herein, statements made in this release that would constitute forward-looking statements may involve certain risks and uncertainties. All forward-looking statements made in this release are based on currently available information and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. The factors include, but are not limited to, risks that may result from changes in the Company’s business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against Arrayit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company’s Form 10-K for the fiscal year ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended March 31, 2008 and Form 10-Q for the fiscal third quarter ended September 30, 2008.